By The METAvivor Advocacy Team
As the calendar turned to January, the advocacy landscape in Washington, D.C., regained its momentum following the winter recess. For the metastatic breast cancer (MBC) community, this period represents a critical window of opportunity. METAvivor has launched into 2026 with a robust, multi-pronged strategy designed to translate grassroots passion into tangible federal policy change. From appropriations battles to legislative co-sponsorship drives, the organization is actively shaping the discourse on cancer research and patient accessibility.
The Federal Funding Landscape: FY 2026 Appropriations
At the heart of the current federal conversation is the Labor-Health and Human Services-Education (LHHS) appropriations bill. This legislation serves as the primary engine for medical research and public health initiatives, and its implications for the MBC community are profound.
Key Budgetary Developments
In mid-January, House and Senate appropriators unveiled proposed funding levels for the upcoming fiscal year. The numbers reflect a broader national acknowledgment of the need for sustained research investment, though advocates argue that more can—and must—be done.
- National Institutes of Health (NIH): The proposed funding stands at $47.216 billion. This represents a $415 million increase over FY 2025 levels, signaling a continued, albeit incremental, commitment to the foundational research that powers breakthroughs in oncology.
- National Cancer Institute (NCI): Within the NIH umbrella, the NCI is slated for $7.352 billion—a $128 million increase. While any increase is a positive step, METAvivor remains vigilant in ensuring these dollars are directed toward high-impact research that addresses the unique, terminal nature of stage IV breast cancer.
- ARPA-H: The Advanced Research Projects Agency for Health remains flat at $1.5 billion. While the agency is relatively new, its role in accelerating “moonshot” style medical innovation is a key area for long-term monitoring.
Public Health and Prevention
The proposal includes a $3 million boost for CDC cancer programs, with $1 million specifically earmarked for the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). While early detection is vital for the broader population, METAvivor emphasizes that this cannot come at the expense of those already living with stage IV disease. The organization continues to press for “targeted federal funding”—investments that prioritize longitudinal data collection and research into treatment resistance, which are the primary hurdles for the MBC community.
The Challenge of "Forward Funding"
A significant point of contention in the proposed bill is the language limiting the NIH’s use of multi-year forward funding. Critics and advocates alike fear that this restriction will stifle the pipeline of new, competitive research awards. By constraining how funds are distributed, the bill threatens to reduce the total number of grants available to researchers, potentially stalling the momentum of young scientists entering the field of metastatic research. METAvivor is currently monitoring this language closely as it moves through the legislative process, recognizing that a vibrant, well-funded research ecosystem is the only path toward extending the lives of patients.
Legislative Momentum: Advocacy in the Halls of Congress
METAvivor’s legislative agenda is built on a foundation of bipartisan cooperation. By focusing on practical, actionable policy, the organization has successfully expanded its footprint on Capitol Hill.
Priority Legislation Updates
- The Metastatic Breast Cancer Access to Care Act: This remains the flagship priority. As of late January, the House version of the bill has secured 197 co-sponsors (149 Democrats and 48 Republicans). The steady climb from 194 co-sponsors earlier in the month demonstrates the efficacy of the organization’s ongoing lobbying efforts. In the Senate, where the companion bill was introduced in December, the current focus is on building a robust list of co-sponsors to mirror the momentum seen in the House.
- The Cancer Drug Parity Act: With 26 House co-sponsors (22 Democrats and 4 Republicans), this act remains a key focus for ensuring patients have equitable access to oral chemotherapy medications, which are often subject to prohibitive cost-sharing structures.
- Prior Authorization Reform: Engagement continues with the office of Representative Julie Johnson. Technical discussions are being scheduled with the Congressional Research Service (CRS) to refine the legislative language, ensuring that the bill is not only passed but is technically sound and effective in removing administrative barriers to care.
Data Surveillance and the SEER Strategy
A consistent hurdle in the fight against metastatic breast cancer is the lack of comprehensive, real-time data. METAvivor has doubled down on its focus regarding the Surveillance, Epidemiology, and End Results (SEER) program.
The organization is currently interrogating how federal data systems capture metastatic disease. Currently, the "snapshot" nature of many registries fails to account for the complexities of MBC, such as treatment switches and disease progression. METAvivor is organizing a series of high-level policy discussions to develop an oversight strategy that could force agencies to improve transparency. The goal is simple: you cannot solve a problem you cannot measure. By modernizing SEER, the community hopes to secure the granular data necessary to track patient outcomes and identify regional disparities in care.
Coalition Building: A Unified Voice
No organization can win these fights in isolation. METAvivor’s strength lies in its ability to coordinate with a broad network of partners.
On January 26, METAvivor participated in the "One Voice Against Cancer" (OVAC) meeting in Washington, D.C. This gathering served as a critical alignment session, allowing organizations to present a united front to lawmakers regarding NIH, NCI, and CDC funding.
Furthermore, the collaboration with the Alliance for Breast Cancer Policy has proven instrumental. By working with the Alliance, METAvivor is effectively elevating the conversation around cancer registries. Through shared resources and synchronized messaging, the two organizations are pushing for a national mandate on how metastatic cases are reported, ensuring that the needs of the MBC community are no longer buried in the aggregate data of general breast cancer statistics.
Strengthening the Grassroots: GroundSwell and Beyond
The most potent tool in METAvivor’s arsenal is its advocate base. Recognizing this, the organization has spent January investing in the "infrastructure of advocacy."
Reimagining the State Captain Program
The State Captain program is undergoing a significant transformation. METAvivor leadership is working to clarify expectations, enhance training, and create a more cohesive structure. By providing state captains with better resources, the organization is effectively decentralizing its advocacy—allowing for faster, more localized responses to legislative developments at the state and federal levels.
Preparing for GroundSwell
As preparations for the annual GroundSwell event ramp up, the focus is on virtual advocacy training. These sessions are designed to move beyond the basics, offering advocates the tools to conduct high-level policy discussions with Congressional staff, even from a distance. The aim is to ensure that when the moment arrives to advocate, every participant possesses the confidence and data-driven talking points necessary to move the needle.
Looking Ahead: The Path Forward
The first month of 2026 has set a high bar for productivity. However, the path ahead remains complex. The immediate priorities for the coming weeks include:
- Appropriations Watch: Closely monitoring the floor votes on the LHHS bill and pushing for language that supports research without stifling innovation.
- Prior Authorization Advocacy: Finalizing the technical language with the Congressional Research Service to prepare for a successful bill introduction.
- SEER Oversight: Transitioning from the strategy phase to actionable oversight, specifically targeting gaps in data transparency.
- Conference Presence: Planning for the "Thriving Together: 2026 Conference on Metastatic Breast Cancer," where the organization intends to bridge the gap between patient experience and federal policy action.
As the METAvivor Advocacy Team continues to engage with lawmakers, coalition partners, and the community at large, the objective remains clear: to transform the reality of metastatic breast cancer through sustained, data-driven, and relentless federal advocacy. With the infrastructure now in place and the legislative momentum building, the organization is well-positioned to make 2026 a year of historic progress for all those affected by metastatic breast cancer.
About the Author
